Our sub-analysis including only type 2 DM indicated that the risk of hypoglycemia was higher with SGLT2 inhibitors than with a placebo [RR 1.30 (95% CI 1.01–1.65)] (Supplementary Table S1). This evidence concerns the gene SLC5A2 and Hypoglycemia.